Endothelin Receptor Antagonists
- Name
- Endothelin Receptor Antagonists
- Accession Number
- DBCAT000972
- Description
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECEPTORS.
- Drugs
Drug Drug Description Bosentan A dual endothelin receptor antagonist used to treat pulmonary arterial hypertension. Macitentan An endothelin receptor antagonist used to manage pulmonary arterial hypertension to delay disease progression. Darusentan For the treatment of congestive heart failure and hypertension. Actelion-1 Investigated for use/treatment in cardiovascular disorders, hypertension, and pulmonary hypertension. TBC-3711 Investigated for use/treatment in congestive heart failure, hypertension, and pulmonary hypertension. Atrasentan Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified). Sitaxentan Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure. Enrasentan Investigated for use/treatment in congestive heart failure, chronic obstructive pulmonary disease (COPD), and benign prostatic hyperplasia. BQ-123 BQ-123 has been investigated for the basic science and treatment of Coronary Artery Disease, Aorto-coronary Bypass Grafting, and ST-Elevation Myocardial Infarction. Ambrisentan A selective type A endothelin receptor antagonist used to treat primary pulmonary arterial hypertension and pulmonary arterial hypertension based on diagnostic classifications. Sparsentan An endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. BQ-788 Not Annotated Aprocitentan An endothelin receptor antagonist used for the treatment of uncontrolled hypertension in patients inadequately controlled on other treatments. - Drugs & Drug Targets